5-fluoro-2,2'-cyclocytidine has been researched along with Leukemia, Myeloid, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arlin, Z; Burchenal, JH; Clarkson, B; Comacho, E; Dowling, M; Drapkin, RL; Dufour, P; Gee, TS; Kempin, S; McKenzie, S; Mertelsmann, R; Oettgen, HF; Passe, S; Thaler, HT; To, L | 1 |
| Meyers, PA; Redner, A; Steinherz, PG; Tan, CT | 1 |
1 trial(s) available for 5-fluoro-2,2'-cyclocytidine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol.
Topics: Adolescent; Adult; Aged; Ancitabine; Antineoplastic Agents; Bacterial Vaccines; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Pseudomonas aeruginosa; Random Allocation; Thioguanine | 1981 |
1 other study(ies) available for 5-fluoro-2,2'-cyclocytidine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia.
Topics: Adolescent; Ancitabine; Antineoplastic Agents; Aziridines; Benzoquinones; Bone Marrow; Cell Survival; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male | 1989 |